Morgan Stanley Reiterates Equal-Weight on Ascendis Pharma, Maintains $109 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $109 price target.
June 20, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating on Ascendis Pharma and maintained a $109 price target.
The news is directly related to Ascendis Pharma (ASND) as Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating and maintained a $109 price target. This indicates that the analyst believes the stock is fairly valued and should perform in line with the market. The impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100